S. Baines

发表

The Changing Epidemiology of Clostridium difficile Infections

M. P. Bauer, E. Kuijper, M. Wilcox, 2010, Clinical Microbiology Reviews.

In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection.

M. Wilcox, J. Freeman, C. Chilton, 2014, The Journal of antimicrobial chemotherapy.

Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model.

M. Wilcox, J. Freeman, C. Chilton, 2013, The Journal of antimicrobial chemotherapy.

Mixed infection by Clostridium difficile in an in vitro model of the human gut.

M. Wilcox, W. Fawley, J. Freeman, 2013, The Journal of antimicrobial chemotherapy.

Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.

M. Wilcox, Joanne K. Hobbs, J. Freeman, 2011, The Journal of antimicrobial chemotherapy.

Effects of Exposure of Clostridium difficile PCR Ribotypes 027 and 001 to Fluoroquinolones in a Human Gut Model

M. Wilcox, J. Freeman, S. Baines, 2008, Antimicrobial Agents and Chemotherapy.

Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model.

M. Wilcox, J. Freeman, S. Baines, 2005, The Journal of antimicrobial chemotherapy.

Analysis of biofilm production and expression of adhesion structures of circulating Clostridioides difficile strains from Mexico.

L. Villarreal-Treviño, A. Camacho-Ortíz, S. Baines, 2021, Enfermedades infecciosas y microbiologia clinica.

High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates

L. Villarreal-Treviño, A. Camacho-Ortíz, S. Baines, 2019, PLoS ONE.

Circulation of Highly Drug-Resistant Clostridium difficile Ribotypes 027 and 001 in Two Tertiary-Care Hospitals in Mexico.

L. Villarreal-Treviño, A. Camacho-Ortíz, S. Baines, 2018, Microbial drug resistance.

Characterization of the Sporulation Initiation Pathway of Clostridium difficile and Its Role in Toxin Production

R. Lewis, M. Wilcox, K. Stephenson, 2009, Journal of bacteriology.

Short-Term Genome Stability of Serial Clostridium difficile Ribotype 027 Isolates in an Experimental Gut Model and Recurrent Human Disease

T. Peto, D. Crook, A. Walker, 2013, PloS one.

Measurement of toxin production by Clostridium difficile

M. Wilcox, W. Fawley, J. Freeman, 2006, The Lancet.

Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery.

M. Wilcox, J. Freeman, S. Nicholson, 2013, The Journal of antimicrobial chemotherapy.

In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile

M. Wilcox, P. Warn, J. Freeman, 2015, The Journal of antimicrobial chemotherapy.

In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin.

M. Wilcox, J. Freeman, S. Baines, 2008, The Journal of antimicrobial chemotherapy.

Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection

M. Wilcox, S. Baines, Simon D Baines, 2015, Antibiotics.

Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.

M. Wilcox, J. Freeman, C. Chilton, 2013, The Journal of antimicrobial chemotherapy.

Para-cresol production by Clostridium difficile affects microbial diversity and membrane integrity of Gram-negative bacteria

B. Wren, J. Swann, H. Kaur, 2018, PLoS pathogens.

Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in intestinal microbiome

J. Garcia-Mazcorro, A. Camacho-Ortíz, S. Baines, 2017, PloS one.

Emergence of reduced susceptibility to metronidazole in Clostridium difficile.

E. Kuijper, M. Wilcox, P. Mastrantonio, 2008, The Journal of antimicrobial chemotherapy.

Molecular epidemiology of predominant and emerging Clostridioides difficile ribotypes.

L. Villarreal-Treviño, A. Camacho-Ortíz, S. Baines, 2020 .

Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection.

M. Wilcox, J. Freeman, S. Baines, 2005, The Journal of antimicrobial chemotherapy.

Mecillinam: a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model.

M. Wilcox, J. Freeman, S. Baines, 2009, The Journal of antimicrobial chemotherapy.

Decreasing prevalence of levofloxacin-resistant Streptococcus pneumoniae in Hong Kong , 2001 to 2007

M. Wilcox, J. Freeman, S. Baines, 2009 .

Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.

M. Wilcox, J. Freeman, S. Baines, 2006, The Journal of antimicrobial chemotherapy.

Development and Validation of a Chemostat Gut Model To Study Both Planktonic and Biofilm Modes of Growth of Clostridium difficile and Human Microbiota

M. Wilcox, J. Freeman, S. Nicholson, 2014, PloS one.

Efficacy of Hospital Cleaning Agents and Germicides Against Epidemic Clostridium difficile Strains

M. Wilcox, R. Owens, K. Stephenson, 2007, Infection Control & Hospital Epidemiology.

Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital.

M. Wilcox, W. Fawley, J. Freeman, 2005, The Journal of antimicrobial chemotherapy.

Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model.

M. Wilcox, J. Freeman, S. Baines, 2008, The Journal of antimicrobial chemotherapy.

Developments in Newfoundland and Labrador Offshore Royalties: From Hibernia to Hebron and Back

S. Baines, R. Thrasher, 2014 .

Tolevamer Is Not Efficacious in the Neutralization of Cytotoxin in a Human Gut Model of Clostridium difficile Infection

M. Wilcox, J. Freeman, S. Baines, 2009, Antimicrobial Agents and Chemotherapy.

Tolevamer is not efficacious in the neutralisation of cytotoxin in a human gut 1

M. Wilcox, J. Freeman, S. Baines, 2009 .

Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole.

M. Wilcox, J. Freeman, S. Baines, 2011, The Journal of antimicrobial chemotherapy.

Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model.

M. Wilcox, J. Freeman, S. Nicholson, 2014, The Journal of antimicrobial chemotherapy.

Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.

M. Wilcox, J. Freeman, S. Baines, 2007, The Journal of antimicrobial chemotherapy.

SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model

M. Wilcox, J. Freeman, R. Vickers, 2014, The Journal of antimicrobial chemotherapy.

Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model.

M. Wilcox, J. Freeman, S. Baines, 2009, The Journal of antimicrobial chemotherapy.

Non-Toxigenic Clostridioides difficile Strain E4 (NTCD-E4) Prevents Establishment of Primary C. difficile Infection by Epidemic PCR Ribotype 027 in an In Vitro Human Gut Model

I. Sidorov, W. Smits, M. Wilcox, 2023, Antibiotics.

Molecular epidemiology of predominant and emerging Clostridioides difficile ribotypes.

L. Villarreal-Treviño, A. Camacho-Ortíz, S. Baines, 2020, Journal of microbiological methods.

Emergence of reduced susceptibility to metronidazole in Clostridium difficile.

E. Kuijper, M. Wilcox, P. Mastrantonio, 2008, The Journal of antimicrobial chemotherapy.

Tolevamer Is Not Efficacious in the Neutralization of Cytotoxin in a Human Gut Model of Clostridium difficile Infection

M. Wilcox, J. Freeman, S. Baines, 2009, Antimicrobial Agents and Chemotherapy.